If you are thinking about taking part in a research study, including a clinical trial, there’s a lot to consider. Check out our FAQs, as well as our lists of Ongoing Research Studies below and results from Past Research Studies. Please contact us at if you know of any additional studies or results, or if the recruitment status for a study has changed, etc… You may also be interested in our SomnusNooze articles about Research Studies.
Note: If you are interested in trying a treatment that is not available in your country, a company like WEP Clinical may be able to help you access this treatment.
DISCLAIMER: This listing is provided merely for informational purposes. Listing a study on this site/web page does not mean that it has been independently evaluated by the Hypersomnia Foundation. The safety and scientific validity of a study listed here is the responsibility of the study sponsor and investigators, not the Hypersomnia Foundation. Before making any decision as to whether or not to participate in a particular research study, you should (1) know the risks and potential benefits of that research study, and (2) consult your own healthcare provider.
The Hypersomnia Foundation’s International Registry at CoRDS
Have IH or a related disorder? Be sure to participate in (and keep updating) the Hypersomnia Foundation’s registry at CoRDS (Coordination of Rare Diseases at Sanford). NOW RECRUITING people with IH and all related disorders INTERNATIONALLY! CLICK HERE for more information and to enroll or update. CoRDS is also listed at ClinicalTrials.gov.
And check out some initial results from the registry:
- 2018 Trotti et al, Self-Reported Sleep Inertia in the Hypersomnia Foundation Registry.
- 2020 Trotti et al, IH Symptom and Treatment Insights From the HF Patient Registry.
A Web-Based Observational Study of Patient-Reported Outcomes in Adults With Narcolepsy
This is the Nexus Narcolepsy registry, a joint venture of Jazz Pharmaceuticals, Narcolepsy Network, and Wake Up Narcolepsy. See ClinicalTrials.gov. NOW RECRUITING people with narcolepsy (both with and without cataplexy) INTERNATIONALLY: CLICK HERE to register.
Pregnancy and Medication Registries
NOW RECRUITING pregnant people. If you are taking (or plan to take) any medication while pregnant, we strongly encourage you to participate in Pregnancy Registries to help further knowledge about medication safety during pregnancy. You can find a list of these Pregnancy Registries in the U.S. HERE. For pregnancy registries in other countries, ask your doctor(s) to direct you (and then please share this information with the HF at ). See also HF’s web page Parenthood and Pregnancy: Considerations for People Who Have Hypersomnias.
INTUNE: A Clinical Study in Adults With Idiopathic Hypersomnia (IH)
The INTUNE study is being conducted by Harmony Biosciences to evaluate the safety and efficacy of pitolisant, an investigational medication for treating excessive daytime sleepiness (EDS) in people with idiopathic hypersomnia age 18 years or older.
This clinical study consists of a screening period (up to 28 days), an 8-week Open-Label Phase in which all eligible study participants will receive pitolisant, followed by a 4-week Double-Blind Randomized Withdrawal Phase in which study participants and doctors won’t know who is receiving pitolisant or placebo (a tablet that does not contain study drug).
For more information or to find a participating clinical site visit: NCT05156047 at clinicaltrials.gov or contact Harmony Biosciences by email at .
A Study to Learn How Family Members Are Affected by IH and Narcolepsy
The Behavioral Sleep Medicine Lab at Northwestern University is seeking participants for their EXPLAIN Study (Examination of Partners and Loved Ones of Adults with Idiopathic Hypersomnia and Narcolepsy), to learn how family members are affected by their loved one’s IH/narcolepsy, how family members provide support, and the types of support family members themselves need.
You may be eligible if:
- You live in the United States.
- You are an adult (18 or older).
Eligible volunteers will be asked to complete an online survey that will take approximately 15 minutes.
Participants will not receive any compensation.
Principal Investigator: Jennifer Mundt, PhD / STU00216960
Pathophysiology of Narcolepsy and Idiopathic Hypersomnia: a Multimodal Neuroimaging Study
NOW RECRUITING people with IH and narcolepsy (no geographical restriction, but if participants come from another time zone, they will require some adaptation to the study time zone prior to beginning the study). The project is to investigate brain regions underlying narcolepsy (with or without cataplexy) and idiopathic hypersomnia. The study includes an MRI scan session and two (non-consecutive) overnight sleep sessions at the sleep laboratory at the Institut Universitaire de Gériatrie de Montréal Research Center on Queen Mar Road in Montreal, Canada. Inclusion criteria are (1) Diagnosis of idiopathic hypersomnia or narcolepsy with or without cataplexy; (2) Age of 18 or more. Exclusion criteria are (1) Other sleep disorders; (2) Neurological disorders or head trauma; (3) Psychiatric disorders or use of psychotropic drugs; (4) Pregnancy or breastfeeding; (5) Pacemaker or metallic prosthesis. Participants will receive Can$200 of compensation if they complete the full study. For travel costs (if required, for those from other provinces or countries), up to Can$150 in travel reimbursements can be provided. If interested, please contact Elizaveta Frolova, Research Coordinator, via email: .
Hypersomnias and the Microbiome
NOW RECRUITING normal sleepers in the Atlanta area. Dr. Lynn Marie Trotti and other Emory sleep researchers are looking for participants, ages 18 – 45, for a study investigating how the microorganisms in the gut (known as the “microbiome”) might affect sleepiness. Participation involves a visit to the Sleep Center (12 Executive Park, Atlanta, GA, 30329) for questionnaires and a blood draw, and collecting a stool sample at home to bring back to the Sleep Center. Total time is estimated at 1 hour, and participants will be compensated.
If you are a good sleeper without any diagnosed sleep disorders, please contact Natalie Fernandez (404-778-6114 or ) or Dr. Trotti () for more information.
Clarithromycin Mechanisms in Hypersomnia Syndromes
NOW RECRUITING adults age 18-45 with IH and narcolepsy type 2 at Emory University in Atlanta, GA, U.S.: CLICK HERE. “The purpose of this study is to evaluate a medication called clarithromycin for treating sleepiness in two related conditions, narcolepsy without cataplexy and idiopathic hypersomnia. Studies have shown that clarithromycin can reduce sleepiness, but researchers do not know how clarithromycin does this. This study will look at brain activity (on magnetic resonance imaging [MRI] and electroencephalogram [EEG] brainwaves), inflammation, bacteria living in the gut, and cerebrospinal fluid, to better understand how clarithromycin can reduce sleepiness. This study will recruit 92 participants who will be randomized to receive clarithromycin or a placebo for 14 days.”
Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia
NOW RECRUITING adults with IH or NT2 (who are newly diagnosed and untreated) at Emory University in Atlanta, GA, U.S.: CLICK HERE. “This study will evaluate which medication works better to improve sleepiness. The researchers will also see which medication is better for other symptoms including difficulty waking up and difficulty thinking, as well as seeing which medication causes fewer side [effects]. Finally, this study will see if any information about patients (such as age or sleep study features) predicts responding better to one medication or the other.”
Sodium Oxybate (Xyrem) for Treatment of Excessive Daytime Sleepiness due to IH
NOW RECRUITING adults age 18-60 with IH in FRANCE: CLICK HERE. This study, sponsored by the University Hospital in Montpellier, France, will evaluate the efficacy of sodium oxybate (marketed as Xyrem) on excessive daytime sleepiness in people with idiopathic hypersomnia.
Constitution of a Clinical, Neurophysiological and Biological Cohort for Chronic Sleep Disorders Responsible of Hypersomnolence (Somnobank)
NOW RECRUITING people with hypersomnias in France: CLICK HERE. University Hospital in Montpellier, France is looking for volunteers age 8 and older suffering from chronic sleep disorders. The creation of a Clinical, Neurophysiological and Biological Cohort will focus on collecting data on severity of symptoms and genetic testing of blood samples to better understand the pathophysiology of hypersomnolence. While cohorts of this type have aided the understanding of narcolepsy type 1, the pathophysiology of narcolepsy type 2 (NT2), idiopathic hypersomnia (IH) and Kleine-Levin syndrome (KLS) is still unknown, due to the small number of patients studied. The study is recruiting volunteers according to the following ratio: NT1 (33%), other central hypersomnias (NT2, IH, KLS, 33%), and hypersomnolence secondary to a neurological sleep or vigilance disorder (ADHD, RLS, parasomnias, 33%).
Swiss Primary Hypersomnolence and Narcolepsy Cohort Study (SPHYNCS)
NOW RECRUITING people age 16 to 70 with idiopathic hypersomnia, narcolepsy, or other hypersomnolence disorder in Bern, Switzerland: CLICK HERE. This is an exploratory prospective, national, multi-center cohort study on clinical, electrophysiological and biological biomarkers of disease presentation and course.
RESTORE: Once Nightly Formulation of Sodium Oxybate (FT218) for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy
NOW RECRUITING people age 16 and up with narcolepsy type 1 or 2 in the U.S.: CLICK HERE. The Restore study is an open label study of FT218, a once-nightly formulation of sodium oxybate in people with narcolepsy. This study is evaluating the long-term safety and tolerability of a once-nightly formulation of sodium oxybate for extended-release oral suspension (FT218) and the ability to switch from twice-nightly immediate release sodium oxybate to once-nightly FT218 for people with narcolepsy. For more information or to find a participating clinical site visit https://clinicaltrials.gov/ct2/show/NCT04451668.
As of March 1, 2021, the U.S. FDA has accepted Avadel’s New Drug Application for once-nightly FT218 for review and assigned a target Prescription Drug User Fee Act action date of October 15, 2021. Check out the press release.
For information on the prior phase 3 clinical trial, CLICK HERE (and check out this Aug. 2021 journal article). Also, see Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA (December 2020).
Four-Week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy
NOW RECRUITING adults age 18 to 65 with narcolepsy (with or without cataplexy) in the U.S.: CLICK HERE. “This is a double-blind, randomized, placebo-controlled, multicenter trial of NLS-2 in adult patients with narcolepsy. The study will enroll approximately 60 patients and eligible patients will be treated to receive either NLS-2 or placebo for 4-weeks.”
A Study to Evaluate Safety and Efficacy of SUVN-G3031 in Patients With Narcolepsy With and Without Cataplexy
NOW RECRUITING people with narcolepsy (type 1 and 2) age 18-50 in the U.S.: CLICK HERE for research sites across the U.S. This is a Phase 2 clinical trial of SUVN-G3031, which is an investigational medicine (a histamine H3 receptor inverse agonist, similar to pitolisant, which is a tablet taken once daily). Preclinical information can be found HERE.
This research study is testing the effectiveness of SUVN-G3031 to reduce the symptoms of narcolepsy. Qualified participants will be seen by a doctor and receive all study-related exams, care and medications at no cost. Those who qualify will be asked to participate for approximately 7 weeks, which will include at least 5 visits to their study doctor, and 3 overnight stays for a sleep study. Compensation for time and travel may be available.
SYMPHONY Study: A Study to Assess the Safety and Efficacy of AXS-12 (Reboxetine) in the Treatment of Cataplexy and Excessive Daytime Sleepiness in People With Narcolepsy
NOW RECRUITING people with narcolepsy with cataplexy aged 15 to 75 in the U.S. (click here) and aged 25 to 65 in Canada (click here). The clinical trial is evaluating AXS-12, an oral investigational medication (reboxetine) for cataplexy and excessive daytime sleepiness in people with narcolepsy. Other symptoms of narcolepsy as well as safety will be assessed throughout the study. Compensation for your time and travel may be available. For further information about this research study please see ClinicalTrials.gov.
New Drug GATE-101 for Excessive Daytime Sleepiness or Depression
NOW RECRUITING normal/healthy adults age 18 to 40 in New Jersey, USA: CLICK HERE. This trial is testing the safety, tolerability and phamacokinetics of GATE-101, a metabotropic glutamate type 2/3 receptor antagonist. All glutamate receptors bind with glutamate, an amino acid that functions as an excitatory neurotransmitter. The eventual goal of this treatment is to improve excessive sleepiness or major depressive disorder.
Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1
NOW RECRUITING adults age 18 and up with myotonic dystrophy type 1 in Spain: CLICK HERE. This trial is testing the dietary supplement MYODM, which contains Theobroma cacao and caffeine for the treatment of excessive daytime sleepiness due to myotonic dystrophy type 1 (DM1).
Portable EEG in Narcolepsy Type 1 and Healthy Volunteers
NOW RECRUITING people age 16 to 60 with narcolepsy type 1 and healthy volunteers in the U.S.: CLICK HERE. The study will assess whether a portable EEG device provides an EEG signal comparable to inpatient nPSG (noctural polysomnogram). The frequency and characteristics of wake and sleep patterns and transitions over multiple nights will also be characterized.
Microglial Activation in Narcolepsy Type 1 or KLS: Positron Emission Tomography (PET) Study
NOW RECRUITING people age 10 and older with narcolepsy type 1 or KLS, in France: CLICK HERE. The goal is “to study the cerebral microglial activation in PET in NT1 patients with recent evolution (appearance of the first symptoms – somnolence and cataplexy – less than 2 years ago) in comparison with controls; then analyze the effect of age, and the severity of symptoms on this PET imaging biomarker.”
Study of the Academic and Professional Course of Narcoleptic Patients
NOW RECRUITING children and adults with narcolepsy type 1, in France: CLICK HERE. This study proposes “to establish a comprehensive inventory of educational and professional trajectories of narcoleptic patients in France in order assess the specificity of the difficulties encountered by the people concerned in their life course and to appreciate the attitude of the academic and professional circle with respect to the disease.”